MX2023005689A - Inmunoensayo para detectar quininogeno escindido de alto peso molecular. - Google Patents

Inmunoensayo para detectar quininogeno escindido de alto peso molecular.

Info

Publication number
MX2023005689A
MX2023005689A MX2023005689A MX2023005689A MX2023005689A MX 2023005689 A MX2023005689 A MX 2023005689A MX 2023005689 A MX2023005689 A MX 2023005689A MX 2023005689 A MX2023005689 A MX 2023005689A MX 2023005689 A MX2023005689 A MX 2023005689A
Authority
MX
Mexico
Prior art keywords
molecular weight
high molecular
immunoassay
weight kininogen
detect cleaved
Prior art date
Application number
MX2023005689A
Other languages
English (en)
Inventor
Ryan Faucette
Daniel J Sexton
Janja Cosic
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2023005689A publication Critical patent/MX2023005689A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona métodos de inmunoensayo para detectar un quininógeno escindido de alto peso molecular (HMWK) con alta sensibilidad y especificidad y anticuerpos aislados que se unen específicamente al HMWK escindido.
MX2023005689A 2015-10-19 2018-04-18 Inmunoensayo para detectar quininogeno escindido de alto peso molecular. MX2023005689A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562243505P 2015-10-19 2015-10-19
US201662335311P 2016-05-12 2016-05-12

Publications (1)

Publication Number Publication Date
MX2023005689A true MX2023005689A (es) 2023-05-29

Family

ID=57233867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004763A MX2018004763A (es) 2015-10-19 2016-10-19 Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
MX2023005689A MX2023005689A (es) 2015-10-19 2018-04-18 Inmunoensayo para detectar quininogeno escindido de alto peso molecular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018004763A MX2018004763A (es) 2015-10-19 2016-10-19 Inmunoensayo para detectar quininogeno escindido de alto peso molecular.

Country Status (17)

Country Link
US (2) US10914747B2 (es)
EP (3) EP3365685B1 (es)
JP (3) JP6903648B2 (es)
KR (1) KR20180093897A (es)
CN (2) CN108291917B (es)
AU (2) AU2016340826C1 (es)
BR (1) BR112018007842A2 (es)
CA (1) CA3002747A1 (es)
CO (1) CO2018004289A2 (es)
DK (1) DK3365685T3 (es)
EA (1) EA201891002A1 (es)
ES (2) ES2857552T3 (es)
IL (2) IL312916A (es)
MX (2) MX2018004763A (es)
PL (2) PL3839514T3 (es)
PT (1) PT3365685T (es)
WO (1) WO2017070170A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
WO2015061182A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
CA2927824A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
EP3768298A4 (en) 2018-03-23 2021-12-08 Board of Regents, The University of Texas System HUMAN ANTI-PD-L2 ANTIBODIES AND PROCESSES FOR USE
KR20210025023A (ko) * 2018-06-26 2021-03-08 쿄와 기린 가부시키가이샤 콘드로이틴 황산 프로테오글리칸-5에 결합하는 항체

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JPS63185398A (ja) 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE275583T1 (de) 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH1084995A (ja) * 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) * 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) * 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
LT1981519T (lt) 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CA2696208A1 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2008315938B2 (en) 2007-10-22 2014-11-27 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
WO2010065656A1 (en) 2008-12-02 2010-06-10 Joslin Diabetes Center Method for reducing blood pressure using inhibitors of plasma kallikrein
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011075684A1 (en) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
US10299714B2 (en) * 2010-12-02 2019-05-28 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CA2838984A1 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
EP4234583A3 (en) * 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
MX2015009914A (es) * 2013-02-01 2015-09-25 Becton Dickinson Co Dispositivos de recogida de sangre que contienen aditivos de inhibicion de la via de contacto.
CA2927824A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
WO2015061182A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
KR20220107077A (ko) * 2014-01-21 2022-08-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도

Also Published As

Publication number Publication date
EP3839514A1 (en) 2021-06-23
EA201891002A1 (ru) 2018-11-30
BR112018007842A2 (pt) 2019-04-16
CN108291917B (zh) 2021-08-27
PT3365685T (pt) 2021-03-01
ES2973301T3 (es) 2024-06-19
EP3839514B1 (en) 2023-12-13
JP6903648B2 (ja) 2021-07-14
ES2857552T3 (es) 2021-09-29
WO2017070170A1 (en) 2017-04-27
IL258637A (en) 2018-06-28
MX2018004763A (es) 2018-09-06
US10914747B2 (en) 2021-02-09
JP2023078186A (ja) 2023-06-06
CN108291917A (zh) 2018-07-17
IL312916A (en) 2024-07-01
CA3002747A1 (en) 2017-04-27
KR20180093897A (ko) 2018-08-22
AU2016340826A1 (en) 2018-04-26
PL3839514T3 (pl) 2024-06-10
AU2016340826C1 (en) 2023-05-04
EP3365685B1 (en) 2020-11-25
EP3365685A1 (en) 2018-08-29
JP2021167824A (ja) 2021-10-21
IL258637B1 (en) 2024-06-01
JP2019502095A (ja) 2019-01-24
AU2023200462A1 (en) 2023-03-02
PL3365685T3 (pl) 2021-08-02
CO2018004289A2 (es) 2018-11-22
EP4354146A2 (en) 2024-04-17
US20210270842A1 (en) 2021-09-02
US20180306807A1 (en) 2018-10-25
EP4354146A3 (en) 2024-06-05
AU2016340826B2 (en) 2022-11-24
CN113655228A (zh) 2021-11-16
JP7238027B2 (ja) 2023-03-13
DK3365685T3 (da) 2021-03-01
NZ741448A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
MX2023005689A (es) Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
WO2014165082A3 (en) Antibodies and methods of detection
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
MX2019015016A (es) Ensayos para la deteccion de una sola molecula y uso de los mismos.
BR112015022763A2 (pt) sensores de oxigênio
TR201904997T4 (tr) Modifikasyona bağlı aktivite tahlilleri.
TR201900160T4 (tr) Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler.
BR112016019866A2 (pt) terapias de combinação com anticorpos anti-cd38
WO2015114506A3 (en) Biosensors for the detection of infection and associated maladies
MX2017016647A (es) Anticuerpos y fragmentos anti-vista.
GB2535394A (en) Magnetic location determination in a wellbore
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
MX2016011809A (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
GB201202223D0 (en) Immunoassay for pyrrolidinophenones
CY1121282T1 (el) Μεθοδος ανιχνευσης της μολυνσης απο η.pylori
WO2014172390A3 (en) Methods for detecting cancer metastasis
CY1123180T1 (el) Συστημα ανιχνευσης που αξιοποιει αλυσιδωτη αντιδραση πολυμερασης
MX2017004516A (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
EA201691091A1 (ru) Диагностические реагенты для улучшенной in vivo или in vitro клеточно-опосредованной иммунологической диагностики туберкулеза
BR112016002062A2 (pt) sistema de transmissão que compreende uma polia de direcionamento e uma correia dentada úmida com óleo
WO2014159685A3 (en) Glatiramer acetate response biomarker mrna potency assay
NZ716313A (en) Detection and monitoring of resistance to an imidazothiazole anti-helminthic in nematodes
MX2016010788A (es) Metodos y sistemas para la deteccion rapida de microorganismos utilizando anticuerpos libres.
PL408620A1 (pl) Sposób oraz zestaw do wykrywania komórek białaczkowych opornych na deltanoidy i przeciwciało znajdujące w nim zastosowanie